Skip to content
CancerIndex

Publication

The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis.

Authors not recorded

Cancer2012PMID 21882184stubpubmedProvenance
Source
PubMed
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Run
ING-CIVIC-20260908-000001
Published

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

Data not yet available

No abstract stored. Read on PubMed

Linked entities

Linked entities (3)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Validated 3

Curated evidence

Evidence citing this paper (3)

civicProvenance
Source
CIViC — Clinical Interpretation of Variants in Cancer
Dataset
CIViC evidence items
Version
civic-2026-09-08
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Evidence
expert curation
License
CC0 1.0
PMID
21882184
Run
ING-CIVIC-20260908-000001
Open at source
CuratedShowing 1–3 of 3 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.
TherapyCancerTypeLevelDirection · significanceRating (1–5)StatusEvidenceSource
BRAF V600E3
MEK Inhibitor CI-1040Malignant Thyroid Gland NeoplasmPredictiveBSupports Sensitivity Response—rejected
EID2138

In a meta-analysis of 8 studies, papillary thyroid cancer patients with BRAF V600E mutation had a higher frequency of recurrence and persistent disease compared to those with wildtype BRAF (28.5% vs.… (full text at CIViC)

PMID 21882184 · Kim et al., 2012 · Open in CIViC

civic
RDEA 119Malignant Thyroid Gland NeoplasmPredictiveBSupports Sensitivity Response—rejected
EID2140

In a meta-analysis of 8 studies, papillary thyroid cancer patients with BRAF V600E mutation had a higher frequency of recurrence and persistent disease compared to those with wildtype BRAF (28.5% vs.… (full text at CIViC)

PMID 21882184 · Kim et al., 2012 · Open in CIViC

civic
(prognostic)Thyroid Gland Papillary CarcinomaALIASPrognosticBSupports Poor Outcome3accepted
EID2503

In a meta-analysis of 8 studies, papillary thyroid cancer patients with BRAF V600E mutation had a higher frequency of recurrence and persistent disease compared to those with wildtype BRAF (28.5% vs.… (full text at CIViC)

PMID 21882184 · Kim et al., 2012 · Open in CIViC

civic